Modulation of Clot Structure and Platelet Function by Aspirin in Individuals with Diabetes: the role of aspirin dose and Glycaemic control - Aspirin in Diabetes

niversity of Leeds0 个研究点目标入组 96 人开始时间: 2009年7月6日最近更新: 2020年10月13日

适应症

试验速览

暂无简介。

•patients with type 1 diabetes(T1DM), treated with insulin only
•age 18 - 65
•not taking any other medication
•no significant medical history(see below)
•using reliable contraception ie. oral contraceptive pill, intra-utering device, diaphragm + condom
•Healthy volunteers as above but without T1DM
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Any history of cardiovascular disease.
•Prior treatment with aspirin, clopidogril or warfarin.
•Regular previous or current treatment with non-steroidal anti-inflammatory drugs,
•Current treatment with any medication other than insulin
•History of acute coronary syndrome or stroke, deep vein thrombosis, pulmonary embolism, previous or current upper gastrointestinal pathology, malignancy or coagulation disorders.
•Any individual found to have abnormal liver function (measured by ALT>3 fold upper limit of normal) or abnormal thyroid function will be excluded at this time and offered further investigation.
•Control subjects will be excluded if found to have impaired glucose tolerance or diabetes measured according to current guidelines.
•Not currently using contraception
•Pregnant women will not be included in the study. In the unlikely event of pregnancy during the study, the individual will be immediately withdrawn.

发起方

niversity of Leeds